PFID and nearly 100 health care groups urge Sec. Becerra to support action on PASTEUR

The Honorable Xavier Becerra

Secretary

US Department of Health and Human Services

Washington, DC 20201


October 3, 2022


Dear Secretary Becerra,


On behalf of the undersigned organizations representing health care providers, public health

professionals, scientists, patients, and the pharmaceutical and diagnostics industries, thank you for being the first Secretary of Health and Human Services to attend the World Antimicrobial Resistance (AMR) Congress in September 2022 and for your powerful remarks about the urgent need for action to strengthen the antimicrobial pipeline and ensure optimal antimicrobial use. We strongly agree that we must make the current “moment into a movement” by translating increased attention on AMR into meaningful action to benefit patients. To achieve our common goals, we respectfully request that you call on Congress to advance the PASTEUR Act this year.


The PASTEUR Act continues to gain momentum and currently has over 60 bipartisan cosponsors. We greatly appreciate that the President included a proposal that aligns with PASTEUR in his 2023 budget request, and we were encouraged to see the released Senate Labor-Health and Human Services appropriations bill for 2023 support that proposal. AMR thought leaders broadly agree that PASTEUR would have a transformative effect on the broken antimicrobial pipeline, delivering the novel, life-saving therapeutics that patients desperately need to fight superbugs. PASTEUR would also provide new funding for rural, critical access and safety net hospitals to support antimicrobial stewardship, to ensure that antimicrobials are used appropriately to limit the development of resistance, and to ensure that the vulnerable patients served by these hospitals can have access to the benefits of antimicrobial

stewardship. The time for PASTEUR is now.


Despite broad recognition of the need for action on AMR, congressional leaders have not yet sufficiently prioritized this issue. Delays in the passage of PASTEUR are delays in the development of novel antimicrobials to treat highly resistant, life-threatening infections—delays that many patients, including those particularly susceptible to infections, such as patients with cystic fibrosis, cancer, or organ transplants, cannot afford.


Once again, we thank you for your leadership in the fight against AMR and hope you will direct your passion for solutions at a key audience that is well positioned to advance meaningful change—the US Congress. Our diverse group of stakeholders is united behind PASTEUR, and your voice can help us cross the finish line.


Sincerely,

  • AdvaMedDx

  • Aequor Inc.

  • Allergy & Asthma Network

  • Alliance for Aging Research

  • Alliance for Biosecurity

  • Alpha-1 Foundation

  • American Academy of Allergy, Asthma & Immunology

  • American Brain Coalition

  • American Gastroenterological Association

  • American Society for Microbiology

  • American Society of Transplant Surgeons

  • American Society of Tropical Medicine and Hygiene

  • American Urological Association

  • Amputee Coalition

  • AMR Patient Advocate

  • AMR.Solutions

  • Arthritis Foundation

  • Association for Professionals in Infection Control and Epidemiology

  • Biocom California

  • bioMerieux Inc.

  • Biotechnology Innovation Organization (BIO)

  • BioVersys AG

  • Black, Gifted & Whole

  • Boehringer Ingelheim Venture Fund USA

  • Boomer Esiason Foundation

  • Bugworks

  • Cancer Support Community

  • Clarametyx Biosciences, Inc.

  • Coalition of Skin Diseases

  • Colorectal Cancer Alliance

  • COPD Foundation

  • Cystic Fibrosis Foundation

  • Duke-Margolis Center for Health Policy

  • Emory Antibiotic Resistance Center

  • Entasis Therapeutics

  • Food Animal Concerns Trust

  • Forge Therapeutics, Inc.

  • Foundation for Sarcoidosis Research

  • GARDP North America

  • Genentech, a member of the Roche Group

  • Global Coalition on Aging

  • GSK

  • Health Care Without Harm

  • Healthcare Leadership Council

  • HealthHIV

  • HealthyWomen

  • Hesed Medical Associates

  • HIV Medicine Association

  • Immune Deficiency Foundation

  • Incubate

  • Infectious Diseases Society of America

  • Johns Hopkins Center for a Livable Future

  • Locus Biosciences

  • LUNGevity Foundation

  • Lymphoma Research Foundation

  • Making-A-Difference in Infectious Diseases

  • Merck

  • Michigan Antibiotic Resistance Reduction Coalition

  • Microbion Corporation

  • National Association for Hispanic Elderly

  • National Association of Nutrition and Aging Services Programs

  • National Association of Pediatric Nurse Practitioners

  • National Caucus and Center on Black Aging

  • National Coalition for LGBTQ Health

  • National Consumers League

  • National Hispanic Council on Aging

  • National Hispanic Medical Association

  • National Psoriasis Foundation

  • Novo Holdings

  • Novo Nordisk Foundation

  • NTM Info & Research

  • Omniose

  • One Health Trust

  • Oragenics, Inc.

  • Partnership to Fight Infectious Disease

  • Pediatric Infectious Diseases Society

  • Peggy Lillis Foundation for C. diff Education & Awareness

  • Peptilogics, Inc.

  • Phare Bio

  • Prevent Blindness

  • Renal Physicians Association

  • Sepsis Alliance

  • Seres Therapeutics

  • Shionogi, Inc.

  • Sinsa Labs

  • Spina Bifida Association

  • Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance

  • The Gerontological Society of America

  • The Joint Commission

  • The Pew Charitable Trusts

  • Transcultural Nursing Society

  • Trust for America's Health

  • United Spinal Association

  • Venatorx Pharmaceuticals

  • ZERO - The End of Prostate Cancer